Related Experiment Video
Updated: Jul 13, 2026
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Outcomes of radiofrequency ablation for kidney cancer
Sangtae Park1, Jeffrey A Cadeddu
1Department of Urology, University of Texas, Southwestern Medical Center, Dallas 75390, USA.
Background:
The incidence of small (< 4 cm) solid enhancing renal masses has been rising, and the majority (60% to 80%) of these tumors are renal cell carcinomas (RCCs) when pathologic analysis is performed. Needle ablation for small incidental renal masses is an attractive therapeutic option. Reasons include its decreased morbidity, shorter convalescence, and the ability to avert the higher risk of extirpative surgery in an aging patient population. Radiofrequency ablation (RFA) is a thoroughly studied needle ablative method used for RCC.
Methods:
The current published literature on renal tumor RFA was reviewed. The in vitro experiments, animal studies and clinical experience with RFA for treatment of small RCCs were analyzed and various controversies in renal RFA are presented for discussion.
Results:
Percutaneous and laparoscopic renal RFA can be safely performed and can eradicate small RCCs with cancer specific survival rates over 90% to 95% in many series. While long-term (5 years or greater) cancer control data are not yet available, these intermediate-term results are similar to those achieved with traditional nephron-sparing surgical options. However, the optimal method to perform RFA for renal masses is still evolving.
Conclusions:
While long-term cancer control data are not yet available, the current literature suggests that RFA can effectively eradicate small RCCs. Further research is needed to elucidate the influence of various treatment variables, including impedance vs temperature-controlled RFA, sonographic vs computed tomographic guidance, general anesthetic vs conscious sedation, and radiologist vs urologist delivery of renal RFA.
Insights
Radiofrequency ablation (RFA) effectively treats small renal cell carcinomas (RCCs), offering a minimally invasive option with high survival rates. Further research is needed to optimize RFA techniques for renal tumors.
Area of Science:
- Urology
- Oncology
- Minimally Invasive Surgery
Background:
- Rising incidence of small solid enhancing renal masses, with 60-80% being renal cell carcinomas (RCCs).
- Needle ablation, particularly radiofrequency ablation (RFA), presents an attractive option for small renal masses due to decreased morbidity and shorter recovery.
- RFA offers an alternative to surgery for an aging population at higher risk for extirpative procedures.
Purpose of the Study:
- To review the current literature on renal tumor RFA.
- To analyze in vitro, animal, and clinical studies of RFA for small RCCs.
- To discuss existing controversies and evolving methods in renal RFA.
Main Methods:
- Systematic review of published literature on renal tumor RFA.
- Analysis of in vitro experiments, animal studies, and clinical data.
- Presentation and discussion of controversies in renal RFA.
Main Results:
- Percutaneous and laparoscopic RFA are safe and effective for small RCCs.
- Cancer-specific survival rates exceeding 90-95% are reported in multiple series.
- Intermediate-term results are comparable to traditional nephron-sparing surgery, though long-term data are pending.
Conclusions:
- Current literature suggests RFA can effectively eradicate small RCCs, despite the absence of long-term cancer control data.
- Further research is required to determine optimal RFA parameters and delivery methods.
- Key areas for future research include comparing impedance vs. temperature control, imaging guidance, anesthesia types, and operator expertise.
